Beam Therapeutics (MEX:BEAM) Retained Earnings: MXN-31,296 Mil (As of Mar. 2026)


MEX:BEAM Beam Therapeutics Inc MEX:BEAM
69 GF Score
Price MXN655.00
GF Value MXN616.29
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beam Therapeutics Retained Earnings?

Beam Therapeutics MEX:BEAM 69 Retained Earnings is MXN-31,296 Mil as of Mar. 2026. GuruFocus rates MEX:BEAM with a GF Score™ of 69/100 and a GF Value™ of MXN616.29 (Fairly Valued). The stock has 6 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Beam Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was MXN-31,296 Mil.

Beam Therapeutics's quarterly retained earnings increased from Sep. 2025 (MXN-34,687 Mil) to Dec. 2025 (MXN-29,551 Mil) but then declined from Dec. 2025 (MXN-29,551 Mil) to Mar. 2026 (MXN-31,296 Mil).

Beam Therapeutics's annual retained earnings declined from Dec. 2023 (MXN-20,197 Mil) to Dec. 2024 (MXN-32,673 Mil) but then increased from Dec. 2024 (MXN-32,673 Mil) to Dec. 2025 (MXN-29,551 Mil).


Beam Therapeutics  (MEX:BEAM) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Beam Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Beam Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beam Therapeutics Retained Earnings Chart

Beam Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only -15,760.37 -20,614.33 -20,197.47 -32,673.19 -29,551.30

Beam Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -34,285.92 -33,481.93 -34,687.42 -29,551.30 -31,296.42
MEX:BEAM
69GF Score
Beam Therapeutics Inc MEX:BEAM
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beam Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of MXN-31,296 Mil mean?
Beam Therapeutics (MEX:BEAM) has a Retained Earnings of MXN-31,296 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Beam Therapeutics and its competitors.
Is Beam Therapeutics' Retained Earnings too high?
Beam Therapeutics' current Retained Earnings is MXN-31,296 Mil. Overall, Beam Therapeutics has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Beam Therapeutics' Retained Earnings compare to ELVN and IDYA?
Beam Therapeutics' Retained Earnings of MXN-31,296 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Beam Therapeutics and its competitors. Beam Therapeutics's current Retained Earnings is MXN-31,296 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beam Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Beam Therapeutics (MEX:BEAM) is currently considered Fairly Valued. The stock's GF Value™ is MXN616.29, compared to a current price of MXN655.00 — trading 6.3% above its estimated fair value. The current Retained Earnings is MXN-31,296 Mil. Beam Therapeutics' overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Beam Therapeutics (MEX:BEAM), the current Retained Earnings is MXN-31,296 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beam Therapeutics (MEX:BEAM) Overvalued in 2026?

Based on GuruFocus' analysis, Beam Therapeutics stock appears to be overvalued. The current stock price of MXN655.00 is trading 6.3% above its estimated GF Value™ of MXN616.29. GuruFocus considers Beam Therapeutics to be Fairly Valued.

Key valuation signals for MEX:BEAM:

  • Retained Earnings: MXN-31,296 Mil
  • GF Value™: MXN616.29 vs. price of MXN655.00 (6.3% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:BEAM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beam Therapeutics Business Description

Other Exchanges BEAM:USA
Address 238 Main Street, Cambridge, MA, USA, 02142
Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company operates and manages its business in one operating segment, United States.
69GF Score

Get the complete analysis for MEX:BEAM

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN655.00
Price
MXN616.29
GF Value